Loss of Response to Anti-TNFs: Definition, Epidemiology, and ManagementGiulia Roda, Jean‐Frédéric Colombel, Bindia Jharap et al.|Clinical and Translational Gastroenterology|2016Cited by 724
REMIT-UC: Real-World Effectiveness and Safety of Tofacitinib for Moderate-to-Severely Active Ulcerative ColitisChristopher Ma, Talat Bessissow, Remo Panaccione et al.|The American Journal of Gastroenterology|2022Cited by 45
Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management (The TRIUMPH Study)Neeraj Narula, John Marshall, Brian Bressler et al.|Crohn s & Colitis 360|2024Cited by 11
Effectiveness and Safety of Advanced Combination Treatment in Patients With Refractory Inflammatory Bowel Disease or Concomitant Immune-Mediated Disease or Extraintestinal Manifestations: A Multicenter Canadian StudyVirginia Solitano, Vipul Jairath, Ropo Ebenezer Ogunsakin et al.|The American Journal of Gastroenterology|2025Cited by 10
DOP46 Tofacitinib for hospitalized acute severe Ulcerative Colitis – the TRIUMPH studyNeeraj Narula, John K. Marshall, Farhad Peerani et al.|Journal of Crohn s and Colitis|2024Cited by 8